AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, marking the steepest single-day decline across the entire FTSE 100 index.
The sell-off came after reports emerged that Britain’s largest drugmaker was in talks to acquire Bristol-Myers Squibb Co (NYSE:BMY), a move that left analysts at major brokerages struggling to find a convincing rationale.
Jefferies, which carries a buy rating and a 17,500p price target on AstraZeneca, described the reported talks as more than a “head scratcher” for investors and observers alike.
The broker said it was perplexed by the news given the strength of AstraZeneca’s own growth and innovation profile, arguing the company has rarely needed outside help to drive performance.
Jefferies was direct in its assessment, stating that if there is one company that does not need financial engineering, it is AstraZeneca.
The bank acknowledged that a deal of this scale would create the broadest oncology portfolio in the entire pharmaceutical industry, which carries obvious commercial appeal.
However, Jefferies argued that pipeline assets could be sourced more cheaply elsewhere, as AstraZeneca has been demonstrating through its dealmaking activity in China in recent years.
Bristol-Myers Squibb’s cardiovascular business was characterised as merely incremental, while using a large quantity of premium equity to buy a company on a low earnings multiple struck the analysts as drastic.
Bristol-Myers Squibb currently trades on roughly 11 times forecast 2027 earnings, compared with AstraZeneca’s 15 times, a discount that reflects looming patent expiries on key drugs Eliquis and Opdivo.
Jefferies calculated that near-term earnings accretion from such a deal could reach double digits, but cautioned that accretion is rarely a good way to judge a big strategic move.
The broker’s central objection centred on timing, noting that Bristol’s portfolio would add roughly $30 billion of exclusivity losses arriving before AstraZeneca’s own patent cliff, which does not fall until after 2030.
UBS, which also holds a buy rating on AstraZeneca with a 17,600p price target, said it was surprised by the reports and reached broadly similar conclusions through a different line of analysis.
The Swiss bank noted that large pharmaceutical mergers have historically damaged research productivity, as staff focus on job security during integration rather than advancing the underlying science.
The industry has since pivoted towards large bolt-on deals, such as AstraZeneca’s own purchase of Alexion, which add a new therapeutic adjacency rather than creating overlapping operations across existing franchises.
UBS also flagged extensive overlap across solid tumours, blood cancers, and cardiovascular medicine, with clear duplication between marketed products including Imfinzi and Opdivo likely to invite competition scrutiny.
That degree of overlap would drive substantial cost savings but would also invite a deep competition review and probable divestitures across multiple markets and product lines.
Jefferies raised a political dimension too, noting AstraZeneca would be a British acquirer of one of America’s large pharmaceutical companies at a time when Washington is preoccupied with domestic manufacturing priorities.
UBS wondered aloud whether the reports might in fact relate to a narrower partnership on a single product or franchise rather than a full corporate combination.